ASX:PAR (Australia)  
Paradigm Biopharmaceuticals Ltd logo

Paradigm Biopharmaceuticals Ltd

A$ 1.62 (+6.95%) Oct 5
P/E:
At Loss
P/B:
8.34
Market Cap:
A$ 430.36M ($ 279.05M)
Enterprise V:
A$ 391.31M ($ 253.72M)
Volume:
1.79M
Avg Vol (2M):
916.94K
Also Trade In:
Volume:
1.79M
Market Cap A$:
430.36M
Market Cap $:
279.05M
PE Ratio:
At Loss
Avg Vol (2-Month):
916.94K
Enterprise Value A$:
391.31M
Enterprise Value $:
253.72M
PB Ratio:
8.34
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).
Name Current Vs Industry Vs History
Cash-To-Debt 64.3
Equity-to-Asset 0.84
Debt-to-Equity 0.02
Debt-to-EBITDA -0.02
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 20.95
Distress
Grey
Safe
Beneish M-Score -0.17
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 90.92
9-Day RSI 80.97
14-Day RSI 72.03
6-1 Month Momentum % 10.28
12-1 Month Momentum % -36.36

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.02
Quick Ratio 6.02
Cash Ratio 5.07
Days Sales Outstanding 11080.91
Days Payable 21460.65

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -6.6

Financials

ASX:PAR's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$) 0.079
EPS (TTM) (A$) -0.167
Beta 2.25
Volatility % 47.93
14-Day RSI 72.03
14-Day ATR (A$) 0.080104
20-Day SMA (A$) 1.28225
12-1 Month Momentum % -36.36
52-Week Range (A$) 0.84882 - 2.670556
Shares Outstanding (Mil) 285.01

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Paradigm Biopharmaceuticals Ltd Filings

Document Form Filing Date
No Filing Data

Paradigm Biopharmaceuticals Ltd Analysis

Share your research